Intravenous magnesium sulphate and lignocaine in management of trigeminal neuralgia


Article PDF :

Veiw Full Text PDF

Article type :

Case Report

Author :

Jyoti V Kulkarni, Sachin Patil, Rajashri Sonawane, Chetan Gopal Agrawal

Volume :

5

Issue :

1

Abstract :

Introduction: Trigeminal neuralgia (tn) is characterized by a recurrent, unilateral sharp pain in the distribution of branches of the trigeminal nerve. The prevalence of this condition is about 1 in 25000 people. It responds poorly to traditional analgesics; antiepileptic drugs are effective. Palliation of pain, restoration of therapeutic sleep, maintenance of function, and improvement in quality of life remain the mainstays of treatment. Magnesium could be expected to modulate neuropathic pain by blocking the NMDA receptor calcium ionophore. Intravenous lignocaine blocks neuropathic pain by action on sodium channel and blockade of central hypersensitivity.We want to report a series of 12 cases of resistant trigeminal neuralgia treated by intravenous magnesium sulphate and lignocaine. Materials and Methods: Patients having history of recurrence to the treatment of trigeminal neuralgia in spite of treatment either by antiepileptics or neurolytic block were included in our study. In all patients detail preoperative evaluation and investigations were done. After intravenous catheter, patients received inj. magnesium sulphate 30mg/kg as an infusion in 500 ml of ringer lactate solution over a period of 1 hour followed by inj. lignocaine 2mg/kg in 500 ml of DNS once in a week for consecutive 3 weeks. During the infusion patients were monitored with continuous ECG, pulse oximetry and NIBP. Patients were asked to note the severity of pain measured on visual analogue scale (vas) from 0 to 10 (0 as no pain and 10 as severe pain). Also patients were asked to note the total dose of medications he or she already taking for pain relief, improvement in quality of pain and duration after which pain recurred. Observation: Good pain control was observed in three patients up to nine months and were managed by tab carbamazepine 150 mg once a day after recurrence. Seven patients got recurrence after six months and were managed by tab carbamazepine and tab gabapentine. Recurrences of pain occurred after four months in two patients and were managed by inj. absolute alcohol for neurosis as no effective pain control after antiepileptic. Conclusion: We had observed good pain control more than four months with improved quality of life. Antiepileptic drug dose requirement after recurrence of pain was less as compared to prior to magnesium sulphate and lignocaine therapy in all patients.

Keyword :

 Trigeminal neuralgia, Magnesium sulphate, Lignocaine.